The brazenness of these incompetents defies belief
Dear EDAP Shareholders,
As you know, EDAP has now completed the active prostate cancer patient follow-up phase of its ENLIGHT trial and is working on compiling the large and complex PMA file to be submitted to the U.S. FDA, in view of Ablatherm-HIFU approval. Bringing this new and innovative technology to U.S. patients and physicians will allow them to have access to a non invasive therapy to treat effectively localized prostate cancer, preserving patient’s quality of life.
Going through the Ablatherm-HIFU approval process while successfully developing our US lithotripsy sales constitute major milestones in the development of the Company, we therefore wish to motivate and reward EDAP’s teams who are dedicated and committed to successfully achieve our U.S goals and objectives. To this end, the Board of Directors wishes to implement an incentive stock option program in favor of the US contributive employees of EDAP, with a maximum of 500,000 new shares issued, for which your approval is required.
EDAP’s Board of Directors and management hereby wish to convene our shareholders in an extraordinary assembly meeting, scheduled on December 19, 2012, to request your support for the attached resolutions that are detailed in the enclosed Board report.
In the name of the Board of Directors of EDAP,
I wish to thank you for your continuous support.
Chairman of the Board
EDAP TMS SA